Stockscreener 앱 받기
68.95
2.04%
1.38
시간 외 거래:
68.88
-0.07
-0.10%
Astrazeneca PLC 주식(AZN)의 최신 뉴스
World-first approval supports AstraZeneca's sustainability goals - marketscreener.com
Potential Impact on AstraZeneca (AZN) from U.S. Pharma Pricing E - GuruFocus
FTSE 100 LIVE: Stocks rise on US-China hopes, miners rally whilst AstraZeneca tumbles - Proactive Investors
Executive Order Targets Drug Pricing: Impact on AstraZeneca (AZN - GuruFocus
Eyes on Asia: NIH, Henlius, AstraZeneca - BioXconomy
AstraZeneca (AZN) Gains UK Approval for Eco-Friendly Inhaler Pro - GuruFocus
Why did the AstraZeneca share price just fall, and what should we do? - Yahoo
AstraZeneca Loses Spot as UK’s Most Valuable Company to HSBC - Bloomberg.com
GSK and Astrazeneca shares slump as Trump vows drug price cut - Yahoo
Trump's new pharma policy sends GSK and AstraZeneca shares tumbling - business-live.co.uk
AstraZeneca Obtains Approval for Low-carbon Inhaler from UK's MHRA - marketscreener.com
AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Cha - GuruFocus
AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAZN - ACCESS Newswire
AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Ca - GuruFocus
AstraZeneca’s Imfinzi shows promise in bladder cancer trial By Investing.com - Investing.com UK
AstraZeneca posts positive data for Imfinzi in bladder cancer (AZN:NASDAQ) - Seeking Alpha
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens By Stocktwits - Investing.com India
AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Cancer Treatment | AZN Stock News - GuruFocus
AstraZeneca Pharma India gets CDSCO approval for Enhertu for new breast cancer indication - Medical Dialogues
AstraZeneca’s Imfinzi delays bladder cancer return in high-risk patients - Proactive Investors
AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC - DirectorsTalk Interviews
Astrazeneca Says Imfinzi Improved DFS In Early Bladder Cancer - marketscreener.com
Trump, Starmer hail limited US-UK trade deal, but 10% duties remain - marketscreener.com
AstraZeneca (AZN) Sees Increased Bullish Option Activity | AZN S - GuruFocus
US court shuts down AstraZeneca's challenge to Medicare drug price plan - Reuters
Investors who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class ActionAZN - ACCESS Newswire
High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
June 27th Options Now Available For AstraZeneca - Nasdaq
AstraZeneca Loses Bid to Revive Drug Price Suit on Appeal (1) - Bloomberg Law News
Britain set to strike first deal to cut Trump tariffs - marketscreener.com
Does the GSK or AstraZeneca share price currently offer the best value? - MSN
AstraZeneca (AZN) Achieves Key Milestone with Enhertu in Breast Cancer Trial - GuruFocus
AstraZeneca marks Enhertu trial win in breast cancer (AZN) - Seeking Alpha
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment - Yahoo Finance
AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study - marketscreener.com
First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment - insights.citeline.com
ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Followed By THP Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In High-Risk HER2-Positive Early-Stage Breast Cancer In DESTINY- - marketscreener.com
AstraZeneca (AZN) Sees Positive Results in DESTINY-Breast11 Trial | AZN Stock News - GuruFocus
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief - Proactive Investors
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga
Multiple System Atrophy (MSA) Market Research 2025-2035 - GlobeNewswire Inc.
AstraZeneca and GSK Share Price Slide as Markets React to Vinay Prasad’s FDA Appointment - paginasiete.bo
AstraZeneca plc (LON: AZN) Shares Fall 2.2% in Early Morning Trading - paginasiete.bo
REGAstraZeneca PLCEnhertu improved pCR in early-stage breast cancer - TradingView
AstraZeneca (AZN): Impact of FDA's New Inspection Strategy on Fo - GuruFocus
AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing - Yahoo Finance
AstraZeneca unveils $300M Rockville investment, a boost for MoCo amid federal cuts - The Business Journals
Berenberg: AstraZeneca, Eli Lilly Among Pharmaceutical Companies Set to Gain from US 'Pill Penalty' Update - marketscreener.com
AstraZeneca's (AZN) Calquence Gains EU Approval for Mantle Cell Lymphoma Treatment | AZN Stock News - GuruFocus
AstraZeneca's Calquence gets Europe approval for MCL - Sharecast.com
AstraZeneca Plc Calquence combo approved in EU for first-line MCL - DirectorsTalk Interviews
AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma - marketscreener.com
AstraZeneca: EU Approves Calquence Combination For 1st-line Mantle Cell Lymphoma - Nasdaq
AstraZeneca Says Calquence Combination Approved In EU For 1L MCL - marketscreener.com
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye - Yahoo Finance
Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN - GuruFocus
Trump's Push for Lower Drug Prices Could Impact AstraZeneca (AZN) | AZN Stock News - GuruFocus
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma - BioPharma Dive
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma - Yahoo Finance
AstraZeneca reports success in phase III asthma trials By Investing.com - Investing.com India
AstraZeneca reports success in phase III asthma trials - Investing.com
자본화:
|
볼륨(24시간):